Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Preferred Shares: 2018-2021

  • Autolus Therapeutics' Preferred Shares was N/A to $118,625 in Q4 2021 from the same period last year, while for Dec 2021 it was $118,625, marking a year-over-year change of. This contributed to the annual value of $121,077 for FY2021, which is N/A change from last year.
  • Per Autolus Therapeutics' latest filing, its Preferred Shares stood at $118,625 for Q4 2021, which was down 100.00% from $133,910.4 billion recorded in Q3 2019.
  • Autolus Therapeutics' Preferred Shares' 5-year high stood at $133,910.4 billion during Q3 2019, with a 5-year trough of $118,625 in Q4 2021.
  • Its 2-year average for Preferred Shares is $89,273.4 billion, with a median of $133,909.8 billion in 2019.